logo
Plus   Neg
Share
Email

Cresco Labs Launches Remedi Cannabis Brand In New York

Cresco Labs, a multi-state cannabis operator, said it has launched its Remedi cannabis brand as well as its Renew and Realign spray tinctures and Renew capsules in New York.

Cresco Labs has also received approval from the New York Department of Health for both THC only and 1:1 CBD to THC capsules, spray tinctures, syringes and vape products from its Remedi line.

The company noted that the launch of the Remedi brand is the next step in expanding its branded wholesale business in New York.

"Remedi products are specifically tailored to meet the needs of medical patients, and they come in precise doses and form factors similar to other health and wellness products. Our new-to-market Sativa spray tincture, as well as new-to-market Hybrid and Indica capsules, are the only category-specific spray tinctures and capsules currently offered in the state," said Greg Butler, Chief Commercial Officer at Cresco Labs.

Remedi is a wellness-focused brand that was originally created for patients with existing medical conditions in medical cannabis states. The brand portfolio has evolved to serve wellness-minded adults, including new consumers, who are interested in exploring how cannabis can become part of their personal routine.

The Remedi line of products includes Remedi spray tinctures that come in two market offerings - Renew spray tincture (Sativa, 100mg THC) and Realign spray tincture (1:1, 100mg CBD:100mg THC). Remedi Renew capsules are available in Hybrid and Indica strains, both offering 100mg THC.

The Remedi products recently introduced into New York have been verified as alcohol free, sugar free, gluten free and vegan, Cresco Labs noted. The company added that future Remedi products sold in the market may include additional tincture and capsule options.

Remedi products will be available in New York, initially in Sunnyside stores in Williamsburg, Huntington, New Hartford and Bardonia.

In addition to New York, select Remedi products are currently available in Illinois, Pennsylvania, Michigan, Massachusetts, Arizona and California.

For comments and feedback contact: editorial@rttnews.com

Health News

Follow RTT